Transaction in Own Shares

PureTech Health PLC
30 November 2023
 

30 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

29 November 2023



Number of ordinary shares purchased:

35,923



Highest price paid per share:

160.80p



Lowest price paid per share:

156.60p



Volume weighted average price paid per share:

157.58p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,700,964 ordinary shares in treasury and has 272,767,195 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 272,767,195 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

29/11/2023

09:57:26

134

159.6

XLON

00380258540TRLO0.1.1

29/11/2023

09:57:28

13

158

CHIX

00380258541TRLO0.1.1

29/11/2023

09:57:34

83

160.8

CHIX

00380258551TRLO0.1.1

29/11/2023

09:57:46

438

158

CHIX

00380258568TRLO0.1.1

29/11/2023

09:58:20

33

160.8

XLON

00380258641TRLO0.1.1

29/11/2023

10:14:18

168

160

XLON

00380260881TRLO0.1.1

29/11/2023

10:14:18

495

160

XLON

00380260882TRLO0.1.1

29/11/2023

11:02:32

1767

159.2

XLON

00380267635TRLO0.1.1

29/11/2023

11:02:32

151

158.8

AQXE

00380267636TRLO0.1.1

29/11/2023

11:02:32

140

158.4

BATE

00380267639TRLO0.1.1

29/11/2023

11:02:32

240

158.4

BATE

00380267638TRLO0.1.1

29/11/2023

11:02:32

589

158.6

CHIX

00380267637TRLO0.1.1

29/11/2023

11:02:32

31

158.4

BATE

00380267640TRLO0.1.1

29/11/2023

11:02:32

113

158.4

TRQX

00380267641TRLO0.1.1

29/11/2023

11:02:32

100

158.4

BATE

00380267642TRLO0.1.1

29/11/2023

11:02:33

265

159

XLON

00380267644TRLO0.1.1

29/11/2023

11:02:33

288

159

XLON

00380267643TRLO0.1.1

29/11/2023

11:03:10

33

157.6

XLON

00380267683TRLO0.1.1

29/11/2023

13:00:01

151

157

AQXE

00380280036TRLO0.1.1

29/11/2023

13:00:01

19

157

AQXE

00380280037TRLO0.1.1

29/11/2023

13:51:18

683

158.4

BATE

00380286916TRLO0.1.1

29/11/2023

13:52:06

65

158.4

BATE

00380287158TRLO0.1.1

29/11/2023

13:52:06

18

158.4

BATE

00380287159TRLO0.1.1

29/11/2023

13:52:11

501

158.2

XLON

00380287170TRLO0.1.1

29/11/2023

13:52:11

165

158.2

XLON

00380287171TRLO0.1.1

29/11/2023

13:59:07

767

158.4

BATE

00380288322TRLO0.1.1

29/11/2023

13:59:07

72

157.2

XLON

00380288323TRLO0.1.1

29/11/2023

13:59:07

2

157.2

XLON

00380288324TRLO0.1.1

29/11/2023

13:59:07

14

157.2

CHIX

00380288325TRLO0.1.1

29/11/2023

13:59:07

1693

157.2

XLON

00380288326TRLO0.1.1

29/11/2023

13:59:07

382

157.2

CHIX

00380288327TRLO0.1.1

29/11/2023

13:59:07

132

157.2

CHIX

00380288329TRLO0.1.1

29/11/2023

13:59:07

193

157.2

CHIX

00380288328TRLO0.1.1

29/11/2023

13:59:07

184

157.2

CHIX

00380288330TRLO0.1.1

29/11/2023

13:59:07

273

157.2

CHIX

00380288331TRLO0.1.1

29/11/2023

13:59:08

170

157

AQXE

00380288332TRLO0.1.1

29/11/2023

13:59:08

41

157

BATE

00380288334TRLO0.1.1

29/11/2023

13:59:08

132

157

AQXE

00380288333TRLO0.1.1

29/11/2023

13:59:08

30

157

BATE

00380288335TRLO0.1.1

29/11/2023

13:59:08

440

157

BATE

00380288336TRLO0.1.1

29/11/2023

13:59:08

3

157

BATE

00380288337TRLO0.1.1

29/11/2023

13:59:08

508

157

BATE

00380288338TRLO0.1.1

29/11/2023

13:59:08

113

157

TRQX

00380288340TRLO0.1.1

29/11/2023

13:59:08

113

157

TRQX

00380288339TRLO0.1.1

29/11/2023

13:59:10

500

157

XLON

00380288344TRLO0.1.1

29/11/2023

13:59:10

609

157

XLON

00380288345TRLO0.1.1

29/11/2023

13:59:14

185

157

XLON

00380288351TRLO0.1.1

29/11/2023

14:36:12

223

158.4

XLON

00380296884TRLO0.1.1

29/11/2023

14:36:12

183

158.4

XLON

00380296885TRLO0.1.1

29/11/2023

14:47:30

462

157

BATE

00380301557TRLO0.1.1

29/11/2023

14:57:24

346

158

AQXE

00380306518TRLO0.1.1

29/11/2023

14:59:24

260

157

CHIX

00380307218TRLO0.1.1

29/11/2023

14:59:24

1767

157

XLON

00380307219TRLO0.1.1

29/11/2023

14:59:24

113

157

CHIX

00380307221TRLO0.1.1

29/11/2023

14:59:24

216

157

CHIX

00380307220TRLO0.1.1

29/11/2023

14:59:24

28

157

CHIX

00380307222TRLO0.1.1

29/11/2023

14:59:24

649

157

CHIX

00380307223TRLO0.1.1

29/11/2023

14:59:26

65

156.8

TRQX

00380307235TRLO0.1.1

29/11/2023

14:59:26

113

156.8

TRQX

00380307236TRLO0.1.1

29/11/2023

15:08:35

141

157.6

AQXE

00380311156TRLO0.1.1

29/11/2023

15:15:07

1767

158

XLON

00380314121TRLO0.1.1

29/11/2023

15:15:12

67

157.8

CHIX

00380314195TRLO0.1.1

29/11/2023

15:15:12

522

157.8

CHIX

00380314196TRLO0.1.1

29/11/2023

15:21:03

1767

157.4

XLON

00380316135TRLO0.1.1

29/11/2023

15:21:53

90

157.4

CHIX

00380316441TRLO0.1.1

29/11/2023

15:21:53

511

157

BATE

00380316442TRLO0.1.1

29/11/2023

15:21:53

113

156.8

TRQX

00380316443TRLO0.1.1

29/11/2023

15:21:56

164

156.6

AQXE

00380316455TRLO0.1.1

29/11/2023

15:25:59

1348

156.8

CHIX

00380317819TRLO0.1.1

29/11/2023

15:35:58

885

157.8

CHIX

00380320828TRLO0.1.1

29/11/2023

15:49:12

93

157.8

CHIX

00380325645TRLO0.1.1

29/11/2023

15:49:12

368

157.8

CHIX

00380325646TRLO0.1.1

29/11/2023

16:07:01

55

156.8

CHIX

00380331052TRLO0.1.1

29/11/2023

16:14:03

5

157.8

AQXE

00380334013TRLO0.1.1

29/11/2023

16:15:56

158

156.8

CHIX

00380334780TRLO0.1.1

29/11/2023

16:15:56

203

156.8

CHIX

00380334779TRLO0.1.1

29/11/2023

16:15:56

25

156.8

CHIX

00380334781TRLO0.1.1

29/11/2023

16:15:56

80

156.8

CHIX

00380334782TRLO0.1.1

29/11/2023

16:15:56

68

156.8

CHIX

00380334783TRLO0.1.1

29/11/2023

16:15:56

38

156.8

XLON

00380334785TRLO0.1.1

29/11/2023

16:15:56

1554

156.8

XLON

00380334786TRLO0.1.1

29/11/2023

16:15:56

600

156.8

CHIX

00380334784TRLO0.1.1

29/11/2023

16:15:56

175

156.8

XLON

00380334787TRLO0.1.1

29/11/2023

16:17:20

217

157.4

XLON

00380335390TRLO0.1.1

29/11/2023

16:25:23

255

156.6

XLON

00380339477TRLO0.1.1

29/11/2023

16:27:27

1

156.6

XLON

00380340312TRLO0.1.1

29/11/2023

16:27:27

136

156.6

XLON

00380340311TRLO0.1.1

29/11/2023

16:28:07

41

157.4

BATE

00380340783TRLO0.1.1

29/11/2023

16:28:10

246

157.4

XLON

00380340803TRLO0.1.1

29/11/2023

16:29:35

107

157.6

TRQX

00380341584TRLO0.1.1

29/11/2023

16:29:35

280

157.6

TRQX

00380341585TRLO0.1.1

29/11/2023

16:29:43

93

157.6

TRQX

00380341788TRLO0.1.1

29/11/2023

16:29:43

20

157.6

TRQX

00380341787TRLO0.1.1

29/11/2023

16:29:49

337

157.4

BATE

00380341893TRLO0.1.1

29/11/2023

16:29:49

182

157.4

BATE

00380341894TRLO0.1.1

29/11/2023

16:29:49

3227

157.4

XLON

00380341895TRLO0.1.1

29/11/2023

16:29:49

622

157.4

XLON

00380341897TRLO0.1.1

29/11/2023

16:29:49

36

157.4

XLON

00380341896TRLO0.1.1

29/11/2023

16:29:49

217

157.4

XLON

00380341898TRLO0.1.1

29/11/2023

16:29:49

988

157.4

XLON

00380341899TRLO0.1.1

29/11/2023

16:29:49

457

157.4

XLON

00380341902TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings